Cytokinetics Stock Analysis

Cytokinetics Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 5.26. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. For more info on Cytokinetics please contact Robert Blum at 650 624 3000 or go to https://www.cytokinetics.com.

Cytokinetics Investment Alerts

Cytokinetics Upcoming and Recent Events

Cytokinetics Largest EPS Surprises

View All Earnings Estimates

Cytokinetics Environmental, Social, and Governance (ESG) Scores

Cytokinetics Stock Institutional Investors

Note, although Cytokinetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cytokinetics Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.1 B.

Cytokinetics Profitablity

Management Efficiency

Cytokinetics has return on total asset (ROA) of (0.3011) % which means that it has lost $0.3011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7215) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics' management efficiency ratios could be used to measure how well Cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 4.57 this year, although the value of Return On Tangible Assets will most likely fall to (0.44). At this time, Cytokinetics' Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 1.4 B this year, although the value of Non Current Liabilities Other will most likely fall to about 374 M.

Technical Drivers

As of the 21st of March, Cytokinetics shows the Mean Deviation of 2.2, standard deviation of 3.2, and Risk Adjusted Performance of (0.04). Cytokinetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cytokinetics Price Movement Analysis

Cytokinetics Insider Trading Activities

Cytokinetics Outstanding Bonds

Cytokinetics Predictive Daily Indicators

Cytokinetics Corporate Filings

Cytokinetics Forecast Models

Cytokinetics' time-series forecasting models are one of many Cytokinetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytokinetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytokinetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytokinetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cytokinetics. By using and applying Cytokinetics Stock analysis, traders can create a robust methodology for identifying Cytokinetics entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cytokinetics analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cytokinetics analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cytokinetics stock analysis indicators help investors evaluate how Cytokinetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cytokinetics shares will generate the highest return on investment. By understating and applying Cytokinetics stock analysis, traders can identify Cytokinetics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.